2026 Q2 -tulosraportti
7 päivää sitten
‧36 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 6.8. | ||
2026 Q1 -tulosraportti 12.5. | ||
2025 Q4 -tulosraportti 11.3. | ||
2025 Q3 -tulosraportti 17.11.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
2 päivää sittenVerrica Pharmaceuticals’ latest quarterly report is its second-quarter 2026 filing, dated August 6, 2026. It says the company reached an agreement in principle to settle a securities class action tied to the 2022 litigation, and it recorded a $4.0 million settlement liability with a $2.3 million insurance recovery, for a net expense of $1.7 million
6.8. · MuokattuVerrica Pharmaceuticals has reached a tentative settlement to resolve investor claims that it misled the market about FDA inspection problems at Sterling and the resulting approval risk for VP-102. Outline: In May 2021, the FDA inspected Sterling, a key contract manufacturer for VP-102, and issued a Form 483 tied to quality problems. On September 20, 2021, Verrica disclosed a second complete response letter tied to deficiencies at Sterling, but continued presenting the issues as resolved. In February 2022, the FDA reinspected Sterling, and on May 24, 2022, Verrica disclosed a third complete response letter after Sterling was placed on OAI status. The case has now moved to a tentative settlement. Verrica Pharmaceuticals, Inc. has reached a tentative settlement to resolve investor claims that it misled the market about FDA inspection problems at Sterling and the resulting approval risk for VP-102. Kan bli en blytung børsdag- ·5.8.Does anyone have faith ahead of tomorrow's presentation?
It will be exciting to see if the increase in the sales force has proven to be a good investment. Cash burn is probably a bit more than last quarter, but I hope the ongoing Torii partnership in Japan and the increase in the sales force balance this in a positive direction. It will be interesting to hear how the process with vp-315 has developed as well. I have faith 🤞 - 6.5.Verrica Pharmaceuticals will present additional data from the completed Phase II study of VP-315 (ruxotemitide) in BCC patients at the 2026 Society for Investigative Dermatology (SID) Annual Meeting next week. This includes new, encouraging findings suggesting VP-315 induces abscopal (systemic) effects following local administration. We believe the new data adds further strength to the case for the treatment's potential in this indication and reiterate our fair value of NOK14–18 per share. What’s new? Verrica Pharmaceuticals (Verrica) will present new data at the upcoming Society for Investigative Dermatology Annual Meeting 2026, taking place on 13–16 May, 2026, in Chicago. The dataset provides further insight into abscopal effects observed with VP-315 in the treatment of basal cell carcinoma (BCC), including evidence of tumour reductions in non-injected lesions. What does it mean? The data to be presented demonstrates highly encouraging tumor shrinkage in non-treated lesions. Across 9 subjects, 14 untreated, non-injected lesions showed an overall 67% reduction in size following treatment of injected lesions. The reductions observed ranged from 50–100% in superficial lesions and 25–100% in nodular lesions. Notably, all treated non-target lesions decreased in size regardless of their position relative to sites, including proximal, distal, and contralateral locations. What do we do? Overall, the clinical data generated with VP-315 in BCC have been highly encouraging in our opinion, and these new findings further strengthen our confidence in its potential in this indication. However, the key catalyst we now await is a definitive decision by Verrica to advance into final pivotal studies, which we expect later this year.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
7 päivää sitten
‧36 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 2 päivää sittenVerrica Pharmaceuticals’ latest quarterly report is its second-quarter 2026 filing, dated August 6, 2026. It says the company reached an agreement in principle to settle a securities class action tied to the 2022 litigation, and it recorded a $4.0 million settlement liability with a $2.3 million insurance recovery, for a net expense of $1.7 million
- 6.8. · MuokattuVerrica Pharmaceuticals has reached a tentative settlement to resolve investor claims that it misled the market about FDA inspection problems at Sterling and the resulting approval risk for VP-102. Outline: In May 2021, the FDA inspected Sterling, a key contract manufacturer for VP-102, and issued a Form 483 tied to quality problems. On September 20, 2021, Verrica disclosed a second complete response letter tied to deficiencies at Sterling, but continued presenting the issues as resolved. In February 2022, the FDA reinspected Sterling, and on May 24, 2022, Verrica disclosed a third complete response letter after Sterling was placed on OAI status. The case has now moved to a tentative settlement. Verrica Pharmaceuticals, Inc. has reached a tentative settlement to resolve investor claims that it misled the market about FDA inspection problems at Sterling and the resulting approval risk for VP-102. Kan bli en blytung børsdag
- ·5.8.Does anyone have faith ahead of tomorrow's presentation?It will be exciting to see if the increase in the sales force has proven to be a good investment. Cash burn is probably a bit more than last quarter, but I hope the ongoing Torii partnership in Japan and the increase in the sales force balance this in a positive direction. It will be interesting to hear how the process with vp-315 has developed as well. I have faith 🤞
- 6.5.Verrica Pharmaceuticals will present additional data from the completed Phase II study of VP-315 (ruxotemitide) in BCC patients at the 2026 Society for Investigative Dermatology (SID) Annual Meeting next week. This includes new, encouraging findings suggesting VP-315 induces abscopal (systemic) effects following local administration. We believe the new data adds further strength to the case for the treatment's potential in this indication and reiterate our fair value of NOK14–18 per share. What’s new? Verrica Pharmaceuticals (Verrica) will present new data at the upcoming Society for Investigative Dermatology Annual Meeting 2026, taking place on 13–16 May, 2026, in Chicago. The dataset provides further insight into abscopal effects observed with VP-315 in the treatment of basal cell carcinoma (BCC), including evidence of tumour reductions in non-injected lesions. What does it mean? The data to be presented demonstrates highly encouraging tumor shrinkage in non-treated lesions. Across 9 subjects, 14 untreated, non-injected lesions showed an overall 67% reduction in size following treatment of injected lesions. The reductions observed ranged from 50–100% in superficial lesions and 25–100% in nodular lesions. Notably, all treated non-target lesions decreased in size regardless of their position relative to sites, including proximal, distal, and contralateral locations. What do we do? Overall, the clinical data generated with VP-315 in BCC have been highly encouraging in our opinion, and these new findings further strengthen our confidence in its potential in this indication. However, the key catalyst we now await is a definitive decision by Verrica to advance into final pivotal studies, which we expect later this year.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 6.8. | ||
2026 Q1 -tulosraportti 12.5. | ||
2025 Q4 -tulosraportti 11.3. | ||
2025 Q3 -tulosraportti 17.11.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 |
2026 Q2 -tulosraportti
7 päivää sitten
‧36 min
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 6.8. | ||
2026 Q1 -tulosraportti 12.5. | ||
2025 Q4 -tulosraportti 11.3. | ||
2025 Q3 -tulosraportti 17.11.2025 | ||
2025 Q2 -tulosraportti 12.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- 2 päivää sittenVerrica Pharmaceuticals’ latest quarterly report is its second-quarter 2026 filing, dated August 6, 2026. It says the company reached an agreement in principle to settle a securities class action tied to the 2022 litigation, and it recorded a $4.0 million settlement liability with a $2.3 million insurance recovery, for a net expense of $1.7 million
- 6.8. · MuokattuVerrica Pharmaceuticals has reached a tentative settlement to resolve investor claims that it misled the market about FDA inspection problems at Sterling and the resulting approval risk for VP-102. Outline: In May 2021, the FDA inspected Sterling, a key contract manufacturer for VP-102, and issued a Form 483 tied to quality problems. On September 20, 2021, Verrica disclosed a second complete response letter tied to deficiencies at Sterling, but continued presenting the issues as resolved. In February 2022, the FDA reinspected Sterling, and on May 24, 2022, Verrica disclosed a third complete response letter after Sterling was placed on OAI status. The case has now moved to a tentative settlement. Verrica Pharmaceuticals, Inc. has reached a tentative settlement to resolve investor claims that it misled the market about FDA inspection problems at Sterling and the resulting approval risk for VP-102. Kan bli en blytung børsdag
- ·5.8.Does anyone have faith ahead of tomorrow's presentation?It will be exciting to see if the increase in the sales force has proven to be a good investment. Cash burn is probably a bit more than last quarter, but I hope the ongoing Torii partnership in Japan and the increase in the sales force balance this in a positive direction. It will be interesting to hear how the process with vp-315 has developed as well. I have faith 🤞
- 6.5.Verrica Pharmaceuticals will present additional data from the completed Phase II study of VP-315 (ruxotemitide) in BCC patients at the 2026 Society for Investigative Dermatology (SID) Annual Meeting next week. This includes new, encouraging findings suggesting VP-315 induces abscopal (systemic) effects following local administration. We believe the new data adds further strength to the case for the treatment's potential in this indication and reiterate our fair value of NOK14–18 per share. What’s new? Verrica Pharmaceuticals (Verrica) will present new data at the upcoming Society for Investigative Dermatology Annual Meeting 2026, taking place on 13–16 May, 2026, in Chicago. The dataset provides further insight into abscopal effects observed with VP-315 in the treatment of basal cell carcinoma (BCC), including evidence of tumour reductions in non-injected lesions. What does it mean? The data to be presented demonstrates highly encouraging tumor shrinkage in non-treated lesions. Across 9 subjects, 14 untreated, non-injected lesions showed an overall 67% reduction in size following treatment of injected lesions. The reductions observed ranged from 50–100% in superficial lesions and 25–100% in nodular lesions. Notably, all treated non-target lesions decreased in size regardless of their position relative to sites, including proximal, distal, and contralateral locations. What do we do? Overall, the clinical data generated with VP-315 in BCC have been highly encouraging in our opinion, and these new findings further strengthen our confidence in its potential in this indication. However, the key catalyst we now await is a definitive decision by Verrica to advance into final pivotal studies, which we expect later this year.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt